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Background: This is an update of a previous meta-analysis published in 2005.
Methods: It includes the data published up to march 2010 for a total of 247 papers and 18,300 cases. Cognitive
deficits are examined in 5 different domains: Memory functioning (128 studies), Global cognitive functioning (131
studies), Language (70 studies), Executive function (67 studies), Attention (76 studies). Only controlled studies were
included: patients vs. normal subjects.
Results: Results evidence that in all domains and in all different analyses performed within each domain, patients
show a significant reduction of cognitive efficiency with respect to normal subjects. The between studies
heterogeneity is very high in almost all domains. There are various sources of this heterogeneity (age, sex, sample
size, type of patients, and type of measurement) which contribute to the high degree of not-overlapping
information offered by the single studies.
Conclusions: Our results, based on the current scientific evidence, confirm the previous findings that there is a
generalized impairment of various cognitive functions in patients with schizophrenia when compared to normal
cases. The modalities with which these results are obtained have not changed over the years and the more recent
studies do not modify the high heterogeneity previously found between the studies. This reduces the
methodological quality of the results. In order to improve the methodological quality of the studies performed in
the field of cognitive deficits of patients with schizophrenia, various factors should be taken into account and better
managed in designing future studies.
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There is a vast scientific evidence, accumulated in sev-
eral years of research, that the cognitive functioning of
patients with schizophrenia is characterized by deficits
[1]. An early hypothesis was that these cognitive deficits
might have a progression over time and depend on the
length of disease [2].
More recent evidence indicates that the severity of
cognitive deficits of patients with schizophrenia is
related to age of onset (deficits of patients with early
onset are more severe than those of patients with a late
onset) while, the subsequent length of disease does not
add further deterioration to the deficits already present
at the early stages [3,4].* Correspondence: mario.fioravanti@uniroma1.it
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reproduction in any medium, provided the orMany other studies have made a link between the
functional disability of these patients and their cognitive
impairment [5] but, at the same time, they have put in
evidence the heterogeneous distribution of cognitive de-
terioration in this population of patients [6].
As a whole, the scientific production concerning the
cognitive problems linked to schizophrenia is very large
and prolonged across many decades. Our search, per-
formed 5 years ago on this topic, found 1,275 papers
published up to that time on schizophrenia and cogni-
tive deficits [7] and even more papers were published in
the following 5 years.
There are many problematic hypotheses and uncer-
tainties about the meaning and the origins of the cogni-
tive problems associated with schizophrenia, and these
are still waiting for an answer despite the high and still
growing trend of the scientific production in this area. Itral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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schizophrenia or if they may be linked to intervening
and concomitant factors during the chronic develop-
ment of the disease. These factors could be age, differ-
ences between clinical forms, concomitant treatments,
or severity and length of disease [4].
A common conclusion offered by the different studies
concerning the various aspects of schizophrenia and
cognitive deficits, is the presence of high heterogeneity
of results. Partially, this heterogeneity is due to meth-
odological problems such as the relative small number
of cases of most of the studies, the often unclear
characterization of patients and their clinical history,
and the systematic unbalance between the number of
patients and that of the control groups [7].
Another component of heterogeneity is due to the clinical
diversity of patients included in the different studies where
groups are composed of inpatients in some instances and
of outpatients in other instances, while the majority of
studies present results obtained from an unspecified mix-
ture of both types of patients. In some other studies groups
of patients with different length of disease or with different
types of therapies are indiscriminately put together.
The third component of heterogeneity is the statistical
heterogeneity which includes the chance component of
variance plus the other components due to possible spe-
cific sources. This part of heterogeneity should be the
one which with appropriate procedures could be
explored, but this possibility will be real only after the
offsetting of the obscuring interference of the methodo-
logical and clinical heterogeneity.
The previous meta-analysis that we performed in 2005
was based on distinct cognitive areas of which deficits were
analyzed in separate tables: memory deficits, IQ deterior-
ation, language deficits, executive functioning deficits, and
attention deficits. The presence of a cognitive impairment
was found in all cognitive areas, but it was not possible to
overcome the prevalent component of the methodological
and clinical heterogeneity which emerged from the results.
The present work is an update, after five years, of the
previous meta-analysis and incorporates all the data pro-
duced after the previous review up to March 2010. The
more recent data-sources were identified with the same
criteria used in the previous systematic review.
This meta-analysis principally aims to evaluate the pres-
ence of cognitive differences between patients with schizo-
phrenia and normal cases. No specific cognitive area is
addressed or excluded and those described in this meta-
analysis are empirically defined according to the prevalent
themes of the current scientific literature. The secondary
aim in updating the previous work was to control for the
stability of results in comparison to the results obtained in
the previous meta-analysis and the methodological quality
of the studies.Methods
In order to perform the update of the previous review
the following databases were searched, PubMed, Psy-
cInfo, PsycArticles by these keywords: ‘cognitive deficit*’
AND ‘schizophrenia patients’; ‘controlled study’. Only
data obtained by human subjects and identifiable until
March 2010 were included. No restrictive language se-
lection criteria were applied.
A total of 1,219 works were identified including 700
papers from PubMed, and 654 from PsychInfo and Psy-
cArticles. The 135 papers found from multiple sources
were considered only once.
All papers examined for inclusion concerned controlled
studies with human subjects where patients with schizo-
phrenia were compared to normal subjects in terms of cog-
nitive functioning. The decision for inclusion was taken by
consensus between two of the authors. In case of disagree-
ment, a third author was called in to give his judgment.
After this search, 270 papers were eligible to be added
to the 117 already included to the previous systematic
review (see Figure 1).
Some of the excluded studies were found lacking of
results expressed in numerical form and their data could
not be retrieved even when the authors were contacted
for this reason (a curious example of this lack of numer-
ical data is constituted by several papers published by the
same Journal of which the editorial guidelines required by
the authors to avoid to put numerical tables in their
papers); other papers were excluded because they did not
conform to the inclusion criteria for this meta-analysis. In
particular, we excluded all the studies where the inclusion
of patients was done by selecting the cases on the basis of
a specific stratification by IQ level.
In the following phase, consisting of the data extraction,
more papers were excluded from the 270 already found
compliant with the inclusion criteria, when they were found
part of a series of partial data publications all concerned
with the same study. In these cases, in order to avoid an
unsuitable redundancy of the data included, we accepted
only the data which were found in the most recent of the
publications or which indicated the largest number of cases
among the other papers of the same series.
In conclusion of the data extraction process, 123 new
papers were added to the 117 ones already present in the
previous systematic review for a total of 240 papers. Each
study may have offered data to one (111 papers) or more
than one (129 papers) domains examined in the review.
The analysis of data is articulated on different cogni-
tive domains. This organization is maintained the same
as in the previous meta-analysis, since it still represents
the most inclusive way of ordering the different types of
measurement prevalently used in this field. As a con-
firmation of this, we have found a still growing number
of papers which were carried out in the last years with
Figure 1 Flow chart of studies.
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organization of cognitive domains.
The distribution of the included papers in the various
tables concerning the areas of cognitive functioning is:
1. Memory functioning (128 studies),
2. Global cognitive functioning (131 studies),
3. Language (70 studies),
4. Executive function (67 studies),
5. Attention (76 studies).
The different areas of cognitive functioning are articu-
lated in different analyses as follows (see Table 1):
Memory Functioning
Measures of Memory Efficiency (47 studies). This
analysis includes all data from papers where there
wasn’t a more specific distinction between types of
memory characteristic to be examined (see Additional
file 1: Table S1 and Figure 2).
Measures of Memory Functioning (inpatients only) (17
studies). This analysis includes only those studies from
Additional file 1: Table S1 which were specified to beperformed with inpatients (see Additional file 1: Table
S1 and Figure 3).
Measures of Memory Functioning (outpatients only) (16
studies). This analysis includes only those studies from
the Additional file 1: Table S1 which were specified to be
performed with outpatients (see Additional file 1: Table
S1 and Figure 4).
Digit Span (31 studies). This analysis includes only those
studies which were performed by the Digit Span as a
measure of immediate memory (see Additional file 1:
Table S1 and Figure 5).
LTM (45 studies). This analysis includes only those
studies which were specified to be performed with
measures of long term memory (see Additional file 1:
Table S1 and Figure 6).
STM (56 studies). This analysis includes only those
studies which were specified to be performed with
measures of short term memory (see Additional file 1:
Table S1 and Figure 7).Global cognitive functioning
Measures of IQ (102 studies). This analysis includes
only those studies which were specified to be
performed with measures of IQ or with measures
Table 1 Distribution of the included studies in the different cognitive domains
Measures of Memory Efficiency Digit Span
Altshuler (2004)b; Baldeweg (2004); Bora (2008)b; Braff (1991)b; Braw
(2005)a;b; Brebion (2001) a; Broerse (2001); Buckley (1994); Cadenhead
(1999); Cantor-Graae (1995); Cavézian (2007); Clare (1993); Crespo-
Facorro (1999)a; Egan (2001)b; Frith (1991); Goldberg (1990); Gras-Vincendon
(1994); Hartman (2003)a; Henry (2007)b; Hill (2004)a; Hoff (1998); Holthausen
(2003)a; Joyce (2002)b; Katz (2007); Kiefer (2002)a; Kopelowicz (2005)a;b;
Kravariti (2003)a; Lanser (2002)a; Michel (1998); Minzenberg (2003)b;
Mulholland (2008)a; Nestor (1998)a; Neufeld (1995)a; Niekawa (2007); Park S
(1995)b; Perlstein (2001)b; Rodriguez-Sànchez (2007); Roesch-Ely (2009)a;
Ross (2000)b; Silver (2003); Soriano (2009)b; Stone (1998)a; Stratta (1999 a)a;
Tek (2002)b; Van Erp (2008)b; Weiss (2002)b; Woonings (2002)a.
Achim (2007); Alptekin (2005); Baldeweg (2004); Bertrand (2007);
Birkett (2006); Brébion (2001)a; Brissos (2008); Buckley (1994);
Burbridge (2007); Cohen (1999); Conklin (2002); Deep (2007);
Fucetola (2000); Javitt (1997); Kiefer (2002)a; Kircker (2001);
Kurachi (1994); Leonard (2008); Matsui (2008); Minzenberg (2003)b;
Papageorgiou (2003); Rodriguez-Sànchez (2007); Roiser (2009);
Schuepbach (2004); Silver (2003); Stirling (2006); Stone (1998)a;
Thomas (1996); Waters (2006); Weiler (2009); Wood (2006).
LTM
Barrantes-Vidal (2007); Birkett (2006); Brazo (2002); Buckley (1994);
Conklin (2002); Davidson (1996); Deep (2007); Dickinson (2004);
Dragovic (2005); Evans (2003); Fucetola (2000); Gonzàlez-Blanch
(2008); Green (1985); Gur (2001); Harvey (1988); Harvey (2000);
Heinrichs (2008); Hill (2004b); Hoff (2005); Huges (2002); Kerns
(2007); Kiang (2007); Kim (2003); Kravariti (2003); Leeson (2005);
Leonard (2008); MacDonald (2003); Manning (2009); Menzies (2007);
Michel (1998); Midorikawa (2008); Müller (2004); Nestor (1998);
Ohrmann (2008); Pino (2008); Riley (2000); Schmand (1992);
Schuepbach (2004); Seidman (2003); Skelley (2008); Tendolkar (2002);
Van Beilen (2004); Wang (2008); Wilk (2002); Wood (2006).
STM
Achim (2007); Arango (1999); Barch (2008); Barrantes-Vidal (2007); Birkett
(2006); Brebion (2004); Brissos (2008); Cellard (2010); Chey (2002); Cosman
(2009); Danion (2001); Dickinson (2004); Dragovic (2005); Fucetola (2000);
Goldberg (1998); Gonzàlez-Blanch (2008); Gooding (2002); Gras-Vincendon
(1994); Gur (2001); Harvey (1990); Hazlett (2000); Hill (2004b); Hoff (1992);
Hoff (1998); Hoff (2005); Huddy (2009); Huges (2002); Keefe (2004); Kerns
(2007); Kiang (2007); Kim (2003); Kopelowicz (2005); Landro (1993); Leeson
(2005); Leonard (2008); MacDonald (2003); Manning (2009); Midorikawa
(2008); Muller (2004); Nestor (1998); Ohrmann (2008); Palmer (2010); Pino
(2008); Riley (2000); Schuepbach (2004); Seidman (2003); Skelley (2008);
Snyder (2008); Tendolkar (2002); Van Den Bosch (1992); Verdoux (1995);
Wang (2008); Weickert (2000); Wexler (1998); Wilk (2002); Wood (2006).
Global Cognitive Functioning
Achim (2007); Aloia (1998) a; Baas (2008); Badcock (2005); Badcock
(2008); Barch (2008) b; Barrantes-Vidal (2007) b; Bell (2009); Bertrand
(2007); Besche (1997)a; Bora (2008) b; Braff (1991)b; Brazo (2002)b;
Brazo (2005) b; Brisson (2008); Burbridge (2007) b; Cadenhead (1999);
Cellard (2007)a; b; Cellard (2010); Chen (2008) b; Conklin (2002) a;
Conklin (2005); Cuesta (2007); Danion (2001)b; Deep (2007) b; Dickinson
(2004) b; Doughty (2008) a; Edell (1987) a; Egan (2001)b; Elvevag (2000)a;
Elvevag (2000b)a; Elvevag (2001)a; Elvevag (2003); Frith (1991);
Fucetola (2000) a; Giovannetti (2003)a; Glahn (2000); Gold (2000) b;
Goldberg (1990); Goldstein (1998)b; Gooding (2002)b; Granholm (1991) b;
Granholm (1999); Gras-Vincendon (1994); Grillon ML (2010); Heaton
(1994); Heinrichs (2008) b; Henquet (2005) a; Henry (2007) b; Hoff (1992);
Hoff (1998); Hoff (2005); Huddy (2009); Hughes (2002)b; Javitt (1995);
Javitt (1997) a; Keefe (2004); Kiehl (2005) b; Krabbendam (2000)b;
Kravariti (2003)a; b; Kurachi (1994); Langdon (2002); Lanser (2002)a;
Leeson (2009); Leitman (2006); Leonard (2008); Luck (2008) b; Macdonald
(2003); Manning (2009) a; Martin (2008); McNealy (2003) b; Michel
(1998) b; Midorikawa (2008); Minzenberg (2003) b; Morice (1990);
Morrison-Stewart (1991); Mulholland (2008) a; Nestor (2008); Neufeld
(1978) a; O’ Carroll (1999); Ohrmann (2008)a; Okada (2002)a; Park IH
(2008)b; Penn (1993)a; Perry (Study 1) (2001)a; Perry (Study 3) (2001);
Premkumar (2008)b; Rodriguez-Sànchez (2007); Ross (2000)b; Rund
(2004)a; Sayers (1995)a; Schreiber (1995); Seidman (2003); Silver (2003);
Skelley (2008); Stirling (2001)a; Stirling (2006); Sullivan (1994)a; Vinogradov
(2002)b; Wang (2008)a; Weikert (2000); Zuffante (2001).
Premorbid IQ
Altshuler (2004); Baas (2008); Badcock (2005); Badcock (2008); Baldeweg
(2004); Birkett (2006); Brebion (2004); D’ Argembeau (2008); Doughty
(2008) a; Egan (2001)b; Elvevag (2000)a; Elvevag (2000b)a; Elvevag (2001)a;
Elvevag (2003); Frith (1991); Goldberg (1998); Henry (2007) b; Hill (2004);
Hoff (1992); Horan (2009); Huddy (2009); Hughes (2002)b; Joyce (2002);
Kiehl (2005) b; Kircher (2001); Kuperberg (1998); Leeson (2009); Majoreck
(2009); Manning (2009) a; Menzies (2007); Moritz (2005); Moritz (2008);
Phillips (2000); Roesch-Ely (2009); Roiser (2009); Rossell (1999); Rossell
(2008); Schmand (1992); Smith (1998); Snyeder (2008); Stirling (2001)a;
Stirling (2006); Sullivan (1994)a; Sullivan (2004); Surguladze (2002); Tsoi
(2008); Waters (2006); Wood (2006).
Language
Alptekin (2005); Altshuler (2004); Al-Uzri (2004); Arango (1999)b; Baldeweg
(2004); Barrantes-Vidal (2007); Bora (2008); Braff (1991)b; Brazo (2005);
Brissos (2008); Broerse (2001); Burbridge (2007); Cantor-Graae (1995);
Chino (2006); Cuesta (2007); D’ Argembeau (2008); Danion (2001); Deep
(2007); Docherty (1996); Docherty (1999); Dragovic (2005); Earle Boyer
(1991); Egan (2001)b; Frith (1991); Giovannetti (2003)a; Glahn (2000);
Goldberg (1990); Goldberg (1998)a; Green (1985); Gur (2001); Harvey
(1990); Haskins (1995); Heinrichs (2008); Hoff (2005); Hoff (1992);
Hoffmann (1999); Keefe (2004); Kiefer (2002)a; Kim (2003); Kopelowicz
(2005); Kosmidis (2005); Kuperberg (1998); Leeson (2005); Leonard (2008);
Manning (2009); Matsui (2008); Menzies (2007); Miller (1995); Minzenberger
(2003); Mirsky (1995); Morice (1990); Muller (2004); Myles-Worsley (1991);
Ojeda (2002)a; Paulsen (1994); Pino (2008); Riley (2000); Rossell (1999);
Rossell (2008); Sarfati (1999); Stirling (2006); Stone (1998)a; Szoke (2009);
Tendolkar (2002); Van Beilen (2004); Verdoux (1995); Vinogradov (2002)b;
Wang (2008); Weickert (2000); Wilk (2002).
Executive Function
Altshuler (2004); Arango C. (1999)b; Bertrand (2007); Bersche-Richard
(1999); Braff (1991)b; Brankovic (1999); Braw (2008); Brazo (2002)b;
Brazo (2005); Cadenhead (1999); Cantor-Graae (1995); Cavèzian (2007);
Corrigan (1991); Egan (2001)b; Fucetola (2000); Glahn (2000); Gold (2000);
Goldberg (1990); Goldberg (1998)a; Gooding (2002)b; Gur (2001); Henry
(2007) b; Hill (2004); Hoff (1992); Hoff (1998); Hoff (2005); Hughes (2002)b;
Keefe (2004); Kesserl (2007); Kiang (2007); Kim (2003); Kopelowicz (2005);
Lanser (2002)a; Lee (2007); Leeson (2009); Manning (2009) a; Michel
(1998); Midorikawa (2008); Minzenberg (2003); Mirsky (1995); Morice
(1990); Moritz (2008); Nestor (2008); Ohrmann (2008); Ojeda (2002)a;
Parellada (1994); Paulsen (1994); Perlstein (1998)a; Perry (Study 3) (2001);
Perry (Study 4) (2001); Rief (1991); Riley (2000); Saoud (2000); Sarfati
(1999); Schwartz (1991); Shelley (1996); Silver (2003); Smith (1998); Stirling
(2006); Stratta (2001); Torres (2007); Verdoux (1995); Wang (2008);
Weickert (2000); Woonings (2002)a; Yogev (2004).
Attention
Achim (2007); Altshuler (2004) b; Babin (2007) a; Barch (2003); Bertrand
(2007); Besche (1997)a; Birkett (2006); Birkett (2007); Braw (2008) a; b;
Brazo (2002)b; Brazo (2005) b; Brisson (2008); Broerse (2001); Cantor-
Graae (1995); Carter (1992)b; Chey (2002); Cuesta (2007); Deep (2007) b;
Dragovic (2005) a; Elvevag (2000b); Fucetola (study 1) (1999); Fucetola
(study 2) (1999); Fucetola (2000) b; Giovannetti (2003)a; Glahn (2000);
Goldberg (1990); Gooding (2002)b; Grillon C (1990); Grillon ML (2010);
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Table 1 Distribution of the included studies in the different cognitive domains (Continued)
Gur (2001); Hartman (2003)a; Hirt (1991)a; Hoff (1992); Hoff (1998);
Holthausen (2003) a; Hughes (2002)b; Javitt (1995); Karch (2009);
Kerns (2007); Kim (2003); Kim (2004) b; Kurachi (1994)b; Laplante (1992)a;
Luck (2008)b; MacDonald (2003); Mathews (2004) b; McNealy (2003) b;
Mirsky (1995); Moritz (2001)a; Muller (2004) a; Ober (1995)b; Ojeda (2002)a;
Park S (1995)b; Penn (1993)a; Perlstein (1998)a; Perlstein (2001)b; Perry
(Study 4) (2001)a; Rabinowicz (1996); Riley (2000); Roesch-Ely (2009) a;
Roiser (2009); Schreiber (1995); Sereno (1996); Smid (2009); Smith (1998) b;
Stirling (2001)a; Stirling (2006); Stratta (1999)a; Strik (1993); Surguladze
(2002); Symond (2002) b; Tek (2002)b; Ueno (2004); Van Den Bosh (1992);
Vinogradov (2002)b; Weiss (1992)a; Zuffante (2001).
a : studies with cases as inpatients; b : studies with cases as outpatients.
Figure 2 Measures of Memory Efficiency.
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Figure 3 Measures of memory functioning (inpatients only).
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and Figure 8).
Measures of IQ (inpatients only) (27 studies). This
analysis includes only those studies from Additional file 1:
Table S1.1 which were specified to be performed with
inpatients (see Additional file 1: Table S1 and Figure 9).
Measures of IQ (outpatients only) (27 studies). This
analysis includes only those studies from Additional file 1:
Table S1.1 which were specified to be performed with
outpatients (see Additional file 1: Table S1 and Figure 10).Figure 4 Measures of memory functioning (outpatients only).Premorbid IQ (48 studies). This analysis includes only
those studies which were specified to be performed
with measures of premorbid IQ as described by
the authors (see Additional file 1: Table S1 and
Figure 11).
Language
Verbal functioning (70 studies). This analysis includes
measures of fluency, naming tasks, etc. (see Additional
file 1: Table S1 and Figure 12).
Figure 5 Digit span.
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Measures of cognitive flexibility (67 studies). This
analysis includes tasks principally obtained from the
Wisconsin Card Sorting Test (see Additional file 1:
Table S1 and Figure 13).Attention
Reaction Time (76 studies). This analysis includes the
reaction time registered with various techniques and in
various types of tasks (see Additional file 1: Table S1
and Figure 14).
Attention (inpatients only) (19 studies). This analysis
includes only those studies where it was specified that
the cases were inpatients (see Additional file 1: Table
S1 and Figure 15).
Attention (outpatients only) (21 studies). This table
includes only those studies where it was specified that
the cases were outpatients (see Additional file 1: Table
S1 and Figure 16).
In general, since there isn’t any substantial change
with respect to the measures utilized in the previous re-
view, the same detailed descriptive table of the measuresfound in the previous review is valid also for this
updated version [7].
Description of the studies
The clinical criteria to individuate and select the
patients of the studies added to this review are the
same as those of the previous version (in general they
were defined according to DSM III, DSM III R, DSM
IV, DSM IV-TR, ICD 9, ICD 10, and RCD the Research
Diagnostic Criteria). Only in few instances there was a
distinction of patients according to different types of
diagnosis, but since this information is present in very
few papers, it has not been utilized for this review. The
total number of cases of this updated version of the re-
view is 18,049: 10,120 patients of the Schizophrenia
Group (SG) and 7,929 normal cases of the Control
Group (CG).
As shown in Table 2, the unbalance between the num-
ber of patients and that of the normal cases is persistent
and generalized in all analyses but one. It ranges be-
tween a maximum of 38% of patient surplus with respect
to the normal cases to a minimum of 12%. Only the
Figure 6 Long term memory.
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number of patients and normal cases. The systematic
unbalance between the groups was already identified in
the previous review and it has remained unchanged in
the more recent papers. This unbalanced design is not
due to few big studies where there was a an asymmet-
rical recruitment of patients and controls, but it is due
to a generalized and persistent modality of recruitment
of the great majority of studies.
The mean age of cases described in the single studies
ranges between a minimum of 16.5 years for patients ofthe SG and of 16.2 years of the CG to a maximum of
73.3 years in both groups.
Not all the studies describe the composition of their
cases and patients by sex. When this information is
available, the mean percentage of males is 70.60% in the
SG and 60.81% in the CG with a range from a minimum
of 0% (all females) to a maximum of 100% (all males).
The average number of male cases of the CG is 87% of
the average number of male patients of the SG.
In general, most of the patients were examined
while taking antipsychotic drugs but it is very rare to
Figure 7 Short term memory.
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or the eventual suspension of it in occasion of the
cognitive evaluation. In few instances, it is indicated
that therapies different from antipsychotic drugs werealso administered to the patients such as BZD, anti-
depressants, etc.
Many studies do not specify if patients were examined
in an acute, chronic, or remission phase.
Figure 8 Measures of IQ.
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Figure 9 Measures of IQ.
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the single papers.
Data analysis
All analyses are performed comparing patients with schizo-
phrenia to normal cases using Review Manager (RevMan)
Version 5.1., Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2011. All variables used are
continuous measures which are analyzed by the Standar-
dized Mean Difference, Random Effect Models, due to di-
versity of methods of measurement used in each analysis,
to the randomness of patients sampling empirically done in
each of the included studies, and to the high level of hetero-
geneity of their variance. The heterogeneity is also quanti-
fied by the index I2 [8] which indicates the part of variance
due to the presence of specific causes different from chance
but not equally distributed in all the studies considered. In
those instances where the original data were presented as
different subgroups of patients, these data were recom-
puted in order to be inserted as a single group of patients.
The type of studies included in this meta-analysis does
not require a quality assessment of the randomization
procedure of allocation of cases. It has other qualityassurance requirements, mostly devoted to warrant a
sound methodological quality of results. The quality ana-
lysis was carried out adopting the method proposed by
Egger et al. [9] which evaluates the presence of interfering
factors on the results by the method of meta-regression.
The meta-regression was used to investigate the relation-
ship of sex, age, and number of participants with the mag-
nitude of the effect size of the single cognitive areas.
Finally, the effect size of each cognitive function was
transformed according to the method proposed by
Grissom [10] to the probability of superiority estimate
(PS index) which allows for the quantification of the
probability [11] that a case from the schizophrenia group
will present a score different from that obtained by a




In this cognitive area concerning the measures of mem-
ory functioning, the comparison between 2,066 patients
with schizophrenia and 1,366 normal subjects (47 stu-
dies for a total of 3,432 cases) produces an ES =−1.22
[-1.44, -1.01] with an I2 = 86% and a PS = 81%. These
Figure 10 Measures of IQ (outpatients only).
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memory functioning among the patients with schizo-
phrenia confirmed by the high probability (81%) to find
a patient with a memory impairment vs. a 19% of prob-
ability to find a patient with scores similar to those of a
normal case. The high heterogeneity of these studies limits
the usefulness of these findings, since it is not possible to
exclude that factors other than the diagnosis could
contribute, at least partially, to determine the difference
between patients and normal subjects (see Table 2).
The results obtained for the same area, separating
inpatients from outpatients, apparently show that outpa-
tients have a larger difference from normal subjects but
also maintain a very large amount of heterogeneity
between studies (respectively: inpatients, ES =−1.21
[-1.63, -0.80], I2 = 90%, PS = 80%; outpatients, ES =−1.83
[-2.35, -1.31], I2 = 92%, PS = 90%). The number of studies
was similar in both instances. In this analysis, the differ-
ence of ES magnitude between in and out-patients is
only apparent. In fact, their confidence intervals overlap
in a way that let us exclude that the two ES’s can be
considered different.
An example of the influence of the methodological
heterogeneity on the ES is offered by the results con-
cerning data obtained by the systematic use of a singletype of measure in all studies on memory functioning; in
this case the Digit Span. In a total of 2,092 cases from
31 works, there is an ES =−0.67 [-0.81, -0.53] with an I2
51%. These results show that when a source of variance
due to the differences between measurement methods
employed in the different studies is eliminated, there is a
consistent reduction of the effect size (which is still de-
monstrative of a statistically significant difference be-
tween groups) accompanied by a reduction to almost
half of the heterogeneity.
Analysis of data in function of the type of memory model
adopted in the studies was carried out in order to control
for a likely source of heterogeneity. The data allowed us to
separate results concerning short term memory (STM) vs.
those concerning long term memory (LTM). Other models
of memory were not suited for this type of analysis since
specific data were only sporadically available.
When only LTM data are included in the analysis,
from 45 studies for a total of 5,045 cases, ES is −1.14
[-1.32, -0.96], I2 87%, and PS 79%. Similar but slightly
less intense results are obtained for STM data, obtained
from 56 studies for a total of 5,405 cases, where
ES =−1.05 [-1.18, -0.92], I2 77%, PS 77%.
These results show that the separation of the type of
memory model reduces the heterogeneity, while the use
Figure 11 Premorbid IQ.
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eity to a much less amount (from around 90% when put
together to about 80% when separated by memory
model and to 50% when using a single type of measure).
In synthesis, these results show that, without a question,
there is a reduction in memory functioning among the
patients with schizophrenia, whatever the method of
examination. They also demonstrate that, at least for
memory functioning, it would be preferable, in the fu-
ture research activity, to identify a specific method of
measurement to be adopted on the basis of researchhypotheses and feasibility of use in this clinical area,
with respect to the current practice of evaluating mem-
ory functioning with whatever task is occasionally avail-
able at the moment. The heterogeneity would be greatly
reduced and the results would be much more informative.
Global cognitive functioning
This area was evaluated in general, by IQ measures (102
works, 8,416 total cases). The ES is −0.96 [-1.07, -0.85]
with I2 = 80% and PS= 75%. When outpatients’ and inpa-
tients’ results are separated and analyzed, the former
Figure 12 Verbal functioning.
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Figure 13 Measures of cognitive flexibility.
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Figure 14 Reaction time.
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Figure 15 Attention (inpatients only).
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while the latter group has an ES =−1.04 [-1.25, -0.82], I2
77%, PS 77%. These results show how the cognitive im-
pairment is generic and diffuse among the patients with
schizophrenia, in at least 3 patients out of 4, and it isFigure 16 Attention (outpatients only).not dependent on the severity of the disease (inpatients
and outpatients do not differ very much in their results
concerning the IQ).
The data concerning the premorbid IQ, are in general
measured by NART or WRAT or using specific subtests
Table 2 Summary of results
Outcome N Studies N Total cases N SG N CG CG/SG*100 Effect Size C.I. 95% PS I2
1 Memory functioning 128
1.1 Measures of Memory Efficiency 47 3,432 2,066 1,366 66.12 −1.22 [-1.44, -1.01]* 0.81 86%*
1.2 Measures of Memory Functioning (inpatients only) 17 1,183 630 553 87.78 −1.21 [-1.63, -0.80]* 0.80 90%*
1.3 Measures of Memory Functioning (outpatients only) 16 1,162 678 484 71.39 −1.83 [-2.35, -1.31]* 0.90 92%*
1.4 Digit Span 31 2,092 1,209 883 73.04 −0.67 [-0.81, -0.53]* 0.68 51% **
1.5 LTM 45 5,045 2,801 2,244 80.11 −1.14 [-1.32, -0.96]* 0.79 87%*
1.6 STM 56 5,405 3,032 2,373 78.26 −1.05 [-1.18, -0.92]* 0.77 77%*
2 Global cognitive functioning 131
2.1 Measures of IQ 102 8,416 4,760 3,656 76.81 −0.96 [-1.07, -0.85]* 0.75 80%*
2.2 Measures of IQ (inpatients only) 27 1,800 894 906 101.34 −1.04 [-1.25, -0.82]* 0.77 77%*
2.3 Measures of IQ (outpatients only) 27 2,274 1,355 919 67.82 −0.83 [-1.00, -0.66]* 0.72 69%*
2.4 premorbid IQ 48 3,568 2,049 1,519 74.13 −0.57 [-0.70, -0.43]* 0.65 70%*
3 Language 70
3.1 Verbal Tasks 70 6,396 3,962 2,434 61.43 −0.99 [-1.10, -0.87]* 0.76 74%*
4 Executive function 67
4.1 Measures of Flexibility 67 5,257 2,867 2,390 83.36 −1.10 [-1.27, -0.92]* 0.78 88%*
5 Attention 76
5.1 Reaction Time 76 5,333 2,852 2,481 86.99 0.99 [0.86, 1.12]* 0.76 77%*
5.2 Attention (inpatients only) 19 1,399 811 588 72.50 1.34 [0.93, 1.76]* 0.83 91%*
5.3 Attention (outpatients only) 21 1,417 771 646 83.79 1.02 [0.70, 1.34]* 0.76 86%*
SG= Patients with Schizophrenia Group; CG normal control cases group.
CG/SG*100: percentage of control cases with respect of patients.
PS = probability of superiority; I2 = percentage of heterogeneity.
* p < .00001; ** p < .00008.
Fioravanti et al. BMC Psychiatry 2012, 12:64 Page 18 of 20
http://www.biomedcentral.com/1471-244X/12/64of the WAIS considered stable over-time. These data are
based on 48 works for a total number of 3,568 cases and
show an ES=−0.57 [-0.70, -0.43], I2 = 70%, PS 65 =%.
The hypothesis based on the premorbid IQ, that some
cognitive discrepancies are already present in the
patients population years ahead of an explicit expres-
sion of the clinical features of this disease, might be
confirmed by these results, at least in 2 cases every 3.
Naturally, since the largest part of these pre-morbid
data are retroactively reconstructed when the disease
is already diagnosed, it seems necessary a further con-
firmation of this hypothesis by the longitudinal pro-
active method of study where the pre-morbid IQ data
are obtained before the diagnosis.
In general, IQ data confirm the findings already seen for
the memory functioning both in terms of ES and of a large
heterogeneity. It must be noted that the heterogeneity is
around 80% when an homogeneous function is evaluated,
such as the IQ or specific models of memory functioning,
Language
The language functioning was evaluated in 70 works for
a total of 6,396 cases (3,962 SG and 2,434 CG). The ES
is −0.99 [-1.10, -0.87] with I2 = 74% and PS = 76%.Executive function
Data concerning this cognitive area were studied in 67
works for a total of 5,257 cases (2,867 SG and 2,390 CG).
The ES is −1.10 [-1.27, -0.92] with I2 = 88% and PS=78%.
Both measures of language functioning and executive
function show that SG patients obtain significantly
worse results than those obtained by the normal con-
trols. The magnitude of differences is similar to that of
the other areas already examined and the same happens
for the heterogeneity.Attention
Data in this cognitive area are measures of reaction time,
obtained in a variety of techniques and tasks from 76
studies for a total of 5,333 cases (2,852 SG and 2,481
CG). The ES is 0.99 [0.86, 1.12] with I2 = 77% and PS =
76%. When inpatients are separately analyzed from out-
patients, the inpatients’ ES is 1.34 [0.93, 1.76] with
I2 = 91% and PS = 83%, while the outpatients’ ES is 1.02
[0.70, 1.34] with I2 = 86% and PS = 76%. Patients with
schizophrenia have a slower reactivity to stimuli than
normal cases and in particular there is a slight stronger
tendency of this to happen among the inpatients (4 out
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with respect to 3 out of 4 outpatients).
Meta-regression
The ES for every type of analysis was correlated with
number of cases, sex distribution, and age of participants
of each group in order to identify the role of these struc-
tural variables in the identification of the between group
differences expressed in terms of ES.
 The number of cases has a significant effect on the
between group differences for the pre-morbid IQ,
the memory functioning (outpatients only), and the
attention measures (expressed in terms of reaction
time). We must remind that there is a wide and
generalized imbalance between group composition
for all cognitive variables examined in this meta-
analysis (Table 2).
 The composition by sex of the groups has a
significant effect on the between group difference
for the IQ measures, the memory functioning, the
language functioning, the executive function, and
the attention measures. In general, there is an
unbalance of sex composition between the SG and
CG groups (Table 2).
 The age of participants has a significant effect on
between group differences for the executive function
and the attention measures.
In particular, the between group difference on mea-
sures of pre-morbid IQ seems to be partially related
to the unbalance of number of cases in the two groups
(respectively increasing the number of SG patients de-
creases the ES, p < .04, while increasing the number of
CG cases increases it, p < .04). The magnitude of the ES
concerning the IQ measures seems to be related to the
differences in sex distribution, in particular for the SG
group (p < .003) where increasing the number of females
reduces the difference between SG and CG groups. The
memory functioning measures (outpatients only) show
that increasing the number of patients of the SG group
and the number of male cases of the CG decreases the
between group difference. For the language functioning
measures the increment of males in the CG increases
the between group difference (p < .05). For the executive
function measures the increasing of age of the CG
(p < .03) and the number of females patients of the SG
(p < .04) decreases the between group difference. The
measure of RT’s of inpatients shows that increasing the
number of the SG patients decreases the between group
difference (p < .04). The measures of RT’s in general
show that an increase of number of males of the CG
(p < .001) and the age of SG patients (p < .001) increases
the between group difference.All these results show that the reduction of the dis-
crepancies and the unbalance of composition of the
groups, together with the reduction of the heterogeneity,
could produce a parallel reduction of the magnitude of
the ES. For what is possible to see from our analysis,
despite this attenuation of effects, the present differences
would remain significant in most domains.
Conclusions
This updated version of the meta-analysis on cognitive
deficits of patients with schizophrenia evidenced by the
comparison with normal control cases, has confirmed
the stability of the results found in the previous work
[7]. These findings show a generalized presence of cog-
nitive impairment among the patients with schizophre-
nia. These results cannot be considered free of the
potential bias that only controlled studies with positive
results are available in the published evidence, while all
those with negative results are not traceable. The real
possibility of such a bias, should make us consider that
the results obtained in this meta-analysis might be, in
some degree, inflated by an underrepresentation of nega-
tive results.
Another problem is evidenced by the quality analysis
of the included studies. The methodological characteris-
tics of the studies on this cognitive impairment, could be
improved with a better control on the balance of num-
ber of cases, sex composition of the two groups, and, at
a less extent, age of participants. The balance of these
factors will take care of some of the structural dysfunc-
tional characteristics evidenced in this meta-analysis.
The identification of precise and replicable measure-
ment procedures is another of the requirements that have
demonstrated to be useful in reducing the methodological
heterogeneity of the present results. By means of the
standardization of methodology, the studies on cognitive
deficits of patients with schizophrenia might move, from
the current situation where they are mostly descriptive, to
the level where they could be of help in refining and con-
firming explanatory hypotheses concerning the character-
istics and the nature of the cognitive impairment.
In the course of the updating process of this meta-
analysis, various characteristics of the available data have
come to attention. It is of general knowledge that there is
a reduction of cognitive efficiency in patients with schizo-
phrenia, but it is important to consider that the intensity
of this reduction (evidenced by comparing patients’ results
to those of normal cases) is not sufficient to classify most
of the patients’ level of functioning below the normal lim-
its. As an example, the range of mean IQ level, found in
the studies concerning patients is 84–107 which indicates
that in general, the average intellectual abilities of the
groups of patients studied are not below the medium-low
level of classification. Analogous considerations could be
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areas explored, based on the magnitude of the effect sizes
obtained in the analyses.
All the elements evidenced in the discussion, converge
on the high heterogeneity found among the studies. A het-
erogeneity so high as that found in our results, shows that
there are diffuse and structural problems in considering
all the studies performed in this area of research as
belonging to the same class of studies. It is necessary to
reduce the heterogeneity to the only acceptable source in
this area of research, the clinical heterogeneity, dependent
on clinical and functional differences among patients clas-
sified in the same diagnostic area. In order to obtain this
simplification of heterogeneity, it is necessary to eliminate
or control for the other unwanted sources of heterogen-
eity, principally the methodological heterogeneity. This
could be obtained by developing and adopting a standar-
dized and consensus-based set of measurement proce-
dures and criteria for identification and selection of cases
for the groups to be studied. It is possible to foresee from
our results, that improving the methodological models
adopted for each study, there will be a reduction of the
heterogeneity and an attenuation of the differences com-
monly found between patients and normal subjects in
most of the cognitive domains. It seems likely from our
results that even if attenuated, in most cases, these differ-
ences will remain statistically significant.
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